Cipla acquires Inzpera, revises FY26 EBITDA margin guidance

Cipla Limited announced on November 3, 2025, the full acquisition of Inzpera Healthsciences Limited, a company specializing in pediatric pharmaceutical and wellness products. The enterprise value of Inzpera is INR 120 crores, with the purchase consideration for equity and non-convertible redeemable preference shares determined to be ~INR 110.65 crores, subject to adjustments. This strategic move aims to integrate Inzpera's portfolio with Cipla's distribution network, with completion expected within one month.

Inzpera's turnover for FY 2024-25 was INR 26.75 crores, FY 2023-24 was INR 22.05 crores, and FY 2022-23 was INR 20.76 crores.

Concurrently, Cipla released the transcript of its Q2 FY26 earnings conference call and revised its full-year EBITDA margin guidance for FY '26 from 23.5%-24.5% to 22.75%-24%, excluding the Yurpeak business plan.